Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05795595 · ClinicalTrials.gov registry record · Phase 1
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
A Phase 1 study of Pancreatic Adenocarcinoma and Clear Cell Renal Cell Carcinoma, sponsored by CRISPR Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 7
- Study locations
NCT05795595 is a Phase 1 study of Pancreatic Adenocarcinoma and Clear Cell Renal Cell Carcinoma that has completed, run by CRISPR Therapeutics. The registered enrollment target is 19 participants, below the 99,465-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT05795595, a Phase 1 study of Pancreatic Adenocarcinoma and Clear Cell Renal Cell Carcinoma, has completed, sponsored by CRISPR Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors.
Conditions Studied
Interventions
- BIOLOGICAL CTX131
Study Locations (7)
California
- Research Site 3 - Duarte
Illinois
- Research Site 7 - Chicago
Massachusetts
- Research Site 6 - Boston
Missouri
- Research Site 2 - St Louis
North Carolina
- Research Site 4 - Durham
Tennessee
- Research Site 1 - Nashville
Texas
- Research Site 5 - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2023-03-13 |
| Est. Completion | 2025-09-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05795595
The ClinicalTrials.gov registry entry for NCT05795595 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 99,465-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower). The listed sponsor is CRISPR Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which CTX131 is the first listed.
NCT05795595 reports 7 study locations spanning 7 distinct geographic areas - top geographies include California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05795595 about?
NCT05795595 is a clinical study titled "A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors". This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors.
What is the current status of trial NCT05795595?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2023-03-13. Estimated completion is 2025-09-18.
What conditions does trial NCT05795595 study?
This clinical trial studies the following conditions: Pancreatic Adenocarcinoma, Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Malignant Pleural Mesothelioma.
What interventions are being tested in trial NCT05795595?
The interventions under investigation include: CTX131 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05795595?
This trial is sponsored by CRISPR Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05795595 being conducted?
This trial has 7 study locations across California, Illinois, Massachusetts, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
RECRUITING · Phase 1
-
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RECRUITING · Phase 1
-
Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
RECRUITING · Phase 1
-
Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies
RECRUITING · Phase 1
Explore more on PlainTrial
Pancreatic Adenocarcinoma
All registered trials for this condition
Clear Cell Renal Cell Carcinoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.